Long-Term Efficacy and Safety of Avutometinib + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer: Insights from RAMP 201

Description

Rachel Grisham presents long-term safety and efficacy data for Avutometinib + Defactinib in recurrent low-grade serous ovarian cancer, based on findings from the RAMP-201 study presented at the SGO 2026 annual meeting. Discussing long-term follow-up data from the study, highlighting the durable efficacy and manageable safety profile of Avutometinib + Defactinib in recurrent low-grade serous ovarian cancer, with practical insights on patient selection, biomarker testing, sequencing, and toxicity management.

Presented by:

Rachel N. Grisham, MD
Section Head, Ovarian Cancer
Director, Gynecologic Medical Oncology, MSK Westchester
Memorial Sloan Kettering Cancer Center
USA

Moderated by:

	Wendel Naumann, MD Director of Minimally Invasive Surgery in Gynecologic Oncology Carolinas Medical Center Associate Medical Director of Clinical Trials Levine Cancer Institute, Atrium Health USA
	Floor Backes, MD The Ohio State University Wexner Medical Center James Comprehensive Cancer Center USA

Attended previous IGCS webinars? If you have attended IGCS webinars in the past, you may already have an IGCS account and creating a new account is not required. If unsure of your login information, you may reset your information by selecting "Forgot Password" at login or contact education@igcs.org.

Supported in part by

Summary

Availability:

On-Demand

Cost:

FREE

Create Account